Octreotide in Tanzania: NEMLIT level, who can prescribe it and STG references
Octreotide is on Tanzania's National Essential Medicines List (NEMLIT, 7th edition, 2026) at level S (zonal, special and national hospitals). It is not on the DukaDawa pharmacy network yet, so we show no brands or prices for it. The Standard Treatment Guidelines mention it in 4 sections.
Last updated
New to DukadawaRx? Register as a prescriber. Licensed prescribers only; we verify your registration before you can prescribe.
Is octreotide available on the DukaDawa pharmacy network?
Not yet. Octreotide is not in the DukaDawa network catalogue, so we have no brands, prices or stock for it.
Prescribers can still write it on a DukadawaRx prescription, and we show it here as soon as a network pharmacy lists it.
Is octreotide on the NEMLIT, and who can prescribe it?
Yes. Octreotide is on Tanzania's National Essential Medicines List (NEMLIT, 7th edition, 2026) at level S (zonal, special and national hospitals). At level S it may be prescribed by specialists.
- Level
- S (zonal, special and national hospitals)
- Category
- Posterior Pituitary Hormones and Analogues (Hormones and Antihormones)
- Listed forms
- Powder and solvent for prolonged release (LAR), suspension for intramuscular injection 10mg, 20mg, 30mg per vial (Special permission
- Page
- NEMLIT, p. 16
| Level | Facility | Who may prescribe |
|---|---|---|
| A | Dispensary | Specialist, Medical Officer, Dental Officer, Assistant Medical Officer, Clinical Officer, Assistant Clinical Officer |
| B | Health centre | Specialist, Medical Officer, Dental Officer, Assistant Medical Officer, Clinical Officer |
| C | Council or district hospital | Specialist, Medical Officer, Dental Officer, Assistant Medical Officer |
| D | Regional referral hospital | Specialist, Medical Officer, Dental Officer |
| S (listed) | Zonal, special and national hospitals | Specialist |
A medicine is listed from the lowest facility level where it should be available.
Where is octreotide in the Standard Treatment Guidelines?
The Standard Treatment Guidelines (7th edition, 2026) mention octreotide in 4 sections, most often section 22.10.2 Central Nervous System Malignancies > Pituitary Tumors (p. 622). See the STG for treatment details.
- 22.10.2 Central Nervous System Malignancies > Pituitary Tumors, p. 622
- 1.8 Approach to Upper Gastrointestinal Bleeding, p. 39
- 10.5.4.3 Disorders of The Liver and Biliary Tract > Portal Hypertension > Bleeding Esophageal Varices, p. 256
- 22.5.8 Head and Neck Cancers > Thyroid Carcinoma, p. 592
Sections that mention Octreotide, most mentions first. Positions only: see the STG for treatment details.
Related medicines
- DesmopressinNEMLIT S · Not on the DukaDawa network yet
- VasopressinNEMLIT S · Not on the DukaDawa network yet
All posterior pituitary hormones and analogues on the NEMLIT
Sources
- Standard Treatment Guidelines and National Essential Medicines List (STG/NEMLIT), 7th edition, 2026, Ministry of Health, United Republic of Tanzania
Page last updated
STG positions are section numbers and printed page numbers only.
This page supports licensed prescribers and pharmacists. It is not medical advice and does not replace the Standard Treatment Guidelines, the product information or professional judgement. Prices and stock change often: confirm with the pharmacy.